Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748508 | 0.88 | L3MBTL1 (0.44) | MAPTL3MBTL1PTGDR2SMN1; SMN2TP53 | |
| SCHEMBL1780188 | 0.87 | L3MBTL1 (0.45) | MAPTL3MBTL1HTR1AHTR7HTR6 | |
| SCHEMBL27687970 | 0.87 | L3MBTL1 (0.48) | MAPTL3MBTL1HTR7HTR6GAA | |
| SCHEMBL14439419 | 0.86 | MAPT (0.48) | MAPTHTR1AHTR7HTR6GAA | |
| SCHEMBL1749087 | 0.86 | L3MBTL1 (0.44) | MAPTL3MBTL1PTGDR2SMN1; SMN2TP53 | |
| SCHEMBL1777861 | 0.85 | MAPT (0.48) | MAPTHTR1AHTR7HTR6GAA | |
| SCHEMBL1777566 | 0.85 | MAPT (0.45) | MAPTHTR1AHTR7HTR6GAA | |
| SCHEMBL1748920 | 0.85 | L3MBTL1 (0.41) | MAPTL3MBTL1GAAPTGDR2SMN1; SMN2 | |
| SCHEMBL1777928 | 0.85 | MAPT (0.48) | MAPTHTR1AHTR7HTR6GAA | |
| SCHEMBL1778523 | 0.85 | L3MBTL1 (0.43) | MAPTL3MBTL1HTR1AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1990343-B1 | Azaindoles | AVENTIS PHARMA LTD (GB) | 2012-04-04 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2233486-A1 | Azaindoles | Aventis Pharma Limited (GB) | 2010-09-29 | — | — | EP | disclosed |
| EP-1263759-B1 | AZAINDOLES | AVENTIS PHARMA LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| EP-1990343-A2 | Azaindoles | Aventis Pharma Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-7227020-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | disclosed |
| US-6897207-B2 | Azaindoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | MAPT 4861/4885L3MBTL1 2911/4885HTR1A 2237/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | MAPT 3999/4885L3MBTL1 4557/4885HTR1A 1507/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | MAPT 4875/4885L3MBTL1 2911/4885HTR1A 1458/4885 |
| US-20050267304-A1 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | MAP3K20, MAP3K12, MAP3K19 | MAPT 911/4885L3MBTL1 4695/4885HTR1A 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.